Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin — Stella

Home/Ovarian Cancer/Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin

View on ClinicalTrials.gov

Recruiting

Back to Ovarian Cancer trials

Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(2 sites)

United States

Brigham and Women's Hospital, Boston, Massachusetts

Dana-Farber Cancer Institute, Boston, Massachusetts

Key details

Phase

Safety & dosing

Sponsor

Dana-Farber Cancer Institute

Collaborators

Merck Sharp & Dohme LLC

Enrollment target

~32 participants

Started

December 2024

Primary completion

December 2026

Age range

18 Years and older

Sex

Female only

Last updated November 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.